Outstanding regulatory aspects in the European pharmaceutical market

PharmacoEconomics

Volumn 15, Issue 6, 1999, Pages 519-533

  Kanavos, Panos ^a   Mossialos, Elias ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; EUROPE; HUMAN; LEGAL ASPECT; PATENT; POLICY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT;

DRUG INDUSTRY; ECONOMIC COMPETITION; EUROPEAN UNION; PATENTS;

EID: 0033065043     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915060-00001     Document Type: Article

References (62)

1. 1. Directive 89/105. Official J Eur Communities 1989; 40: 8
2. 2. Regulation 1768/92. Official J Eur Communities 1992; 182: 1
3. 3. Commission of the European Communities. Outlines of an industrial policy for the pharmaceutical sector in the European Community, Directorate General III. Brussels: Commission of the European Communities, 1994
4. 4. Regulation 2309/93. Official J Eur Communities 1993; 214: 1
5. 5. Directive 92/26. Official J Eur Communities 1992; 113: 5
6. 6. Directive 92/28. Official J Eur Communities 1992; 113: 13
7. 7. Directive 89/341. Official J Eur Communities 1989; 142: 11
8. 8. Directive 92/27. Official J Eur Communities 1992; 113: 8
9. 9. Directive 92/25. Official J Eur Communities 1992; 113: 1
10. 10. Commission of the European Communities. Draft Treaty of Amsterdam: a Conference of the Representatives of the Governments of the Member States; 19 June 1997; Brussels
11. 11. Commission of the European Communities. COM (95) 661. Brussels: Commission of the European Communities, 1995
12. 12. Committee on Legal Affairs and Citizens' Rights. Report on the proposal for a European Parliament and Council Directive on the legal protection of biotechnological inventions. Brussels: European Parliament, 1997
13. 13. Kanavos P, Mossialos E, Abel-Smith B. American and Japanese (bio)pharmaceutical investment in Europe. Brussels: European Parliament, Directorate General for Research, 1995
14. 14. Commission of the European Communities, Commission communication on the single market in pharmaceuticals: COM (98) 588 [final]. Brussels: Commission of the European Communities, 1998: 6
15. 15. European Court of Justice. Case 215/87: Heinz Schumacher vs. Hauptzollamt Frankfurt am Main (1989)
16. 16. Court of Justice of the European Communities. Case C-120/95: Nicolas Decker vs. Caisse de Maladie des Employés Privés (1997), Luxembourg
17. 17. Council of Ministers of 14 June 1971. Consolidated version of Regulation (EEU) No. 1408/71 on the application of social security systems to employed persons, to self-employed persons and to members of their families moving within the Community. Official J Eur Communities 1992; 35: C325
18. 18. Court of Justice of the European Communities. Case C-158/96: Raymond Kohll vs. Union des Caisses de Maladie (1997), Luxembourg
19. 19. Consolidated version of Regulation (EEU) No. 1408/71 of the Council of 14/06/1971 on the application of social security schemes to employed and self-employed persons, and to members of their families moving within the Community. Official J Eur Communities 1992; 35: C325
20. 20. Consolidated version of Council Regulation (EEU) No. 574/72 of 21/03/1972 regarding the implementation of Regulation 1408/71 on the application of social security schemes to employed persons and to members of their families moving within the Community. Official J Eur Communities 1992; 35: C325
21. 21. Kesteloot K, Pocceschi S, van der Schueren E. The reimbursement of the expenses for medical treatment received by 'transnational' patients in EU countries. Health Policy 1995; 33: 43-57
22. 22. Mossialos E, McKee M, Rathwell T. Health care and the single market [editorial]. Eur J Public Health 1997; 7 (3): 235-7
23. 23. Calnan M, Palm W, Sohy F, et al. Cross-border use of health care: a survey of frontier workers' knowledge, attitudes and use. Eur J Public Health 1997; 7 Suppl. 3: 26-32
24. 24. France G. Cross-border flows of Italian patients within the European Union: an international trade approach. Eur J Public Health 1997; 7 Suppl. 3: 18-25
25. 25. Starmans B, Leidl R, Rhodes G. A comparative study on cross border hospital care in the Euregio Meuse-Rhine. Eur J Public Health 1997; 7 Suppl. 3: 33-41
26. 26. Norman P. Bonn to defy European Court. Financial Times 1998 Jun 6: 2
27. 27. Furniss J. The Bangemann Process: slow progress behind closed doors. Eurohealth 1988; 4 (2): 20-1
28. 28. Commission of the European Communities. Second Round Table: completing the single pharmaceutical market. Frankfurt: Commission of the European Communities, 1997
29. 29. Council of Ministers. On the outlines of an industrial policy in the pharmaceutical sector in the EU: Council resolution of 23 April 1996. Official J Eur Communities 1996; 96/C: 136/04
30. 30. European Court of Justice. Judgement of 5 December 1996 in joint cases C-267/95 Merck vs. Primecrown and C-268/95 Beecham vs. Europharm. Luxembourg: European Court of Justice, 1996: 6285-392
31. 31. Working Group One. The European pharmaceutical market: report. Brussels: European Commission, 1997
32. 32. Working Group Two. The single market in pharmaceuticals: chairman & rapporteur's summary. Brussels: European Commission, 1997
33. 33. Council of Ministers. Council conclusions on the single market for pharmaceuticals. Brussels: Internal Market Council, 1998
34. 34. Commission of the European Communities. Commission communication on the single market in pharmaceuticals: COM (98) 588 [final]. Brussels: Commission of the European Communities, 1998
35. 35. Commission of the European Communities. Frankfurt Roundtable Process: conclusions drawn by Commissioner Bangemann [online]. Available from: URL: http://dg3.eudra.org/frankf/pdf/rt3concl.pdf (accessed 1999 April 19)
36. 36. Commission of the European Communities. Proposal for a Council regulation (EEC) concerning the creation of a supplementary protection certificate for medicine products: COM (90) 101 -SYN 255 [final]. Luxembourg: Commission of the European Communities, 1990
37. 37. Stols H. Generic substitution: evaluating the possibilities and limitations for stimulating generic competition. HR Conference on Successfully Competing in Generics; 22 Nov 1993; London
38. 38. Hardisty B. Agenda for health 1994: your medicine - whose choice? London: Association of the British Pharmaceutical Industry, 1994
39. 39. Danzon PM. The economics of parallel trade. Pharmacoeconomics 1998; 13 (3): 293-304
40. 40. Darba J, Rovira J. Parallel imports of pharmaceuticals in the European Union. Pharmacoeconomics 1998; 14 Suppl. 1: 129-36
41. 41. European Court of Justice. Case 104/75: Offievie van Justice vs. de Peijer (1976). European Community Resolution 613
42. 42. European Court of Justice. Cases C-267/95 and C-268/95: Merck v. Primecrown (1995)
43. 43. Kanavos P. Single currency and monetary union: implications for pharmaceutical spending. Pharmacoeconomics 1998; 13 (1): 9-20
44. 44. Bangemann M. Second Frankfurt Round Table on the single pharmaceutical market. Eurohealth 1998; 4 (2): 19-20
45. 45. Mossialos E, Kanavos P, Abel-Smith B. Criteria for the evaluation of new pharmaceutical substances for the European internal market: innovation - part D. Luxembourg: European Parliament, Scientific and Technological Options Assessment, 1993
46. 46. Joint answer to written questions No. 2367/92, 2368/92, 2370/92 given by Mr Bangemann on behalf of the Commission. Brussels: European Commission, 1992
47. 47. Call for EU definition of innovation. Scrip 1996; 2106: 4
48. 48. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guideline for good clinical practice (ICH EWG E6: Good Clinical Practice). Draft 9, step 3. Yokohama: IFPMA Secretariat Geneva, 1995
49. 49. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Note for guidance on structure and content of clinical study reports (CPMP/ICH/137/95). Step 4, consensus guideline. Yokohama: IFPMA Secretariat Geneva, 1995
50. 50. IFMA Secretariat Geneva. International Conference of Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH-4); 1997 Jul 12-17; Geneva
51. 51. Commission of the European Communities. Concept paper on a directive on the implementation of good clinical practice and clinical trials. Directorate General III/E-3, III/5608/95, rev. Brussels: European Commission, 1995
52. 52. Commission of the European Communities. Expert Group Meeting: the implementation of good clinical practices. Perspectives for research, training and regulatory actions [final report]. Brussels: Commission of the European Communities, 1996
53. 53. Department of Health. Guidelines for the economic evaluation of pharmaceuticals [press release]. London: Department of Health, 1994
54. 54. Maynard A, Bloor K. Regulating the pharmaceutical industry: pricing should be re-negotiated to control research costs and encourage cost effectiveness. BMJ 1997; 315: 200-1
55. 55. Department of Health. The new NHS: modern and dependable. London: HMSO, 1997
56. 56. Commission of the European Communities, Commission communication on the single market in pharmaceuticals: COM (98) 588 [final]. Brussels: Commission of the European Communities, 1998: 19
57. 57. Commission of the European Communities. Communication from the Commission concerning a programme of Community action for rare diseases within the framework for action in the field of public health. Brussels: Commission of the European Communities, 1997
58. 58. Commission of the European Communities. Proposal for a European Parliament and Council Regulation on orphan medicinal products [preliminary draft]. Brussels: Commission of the European Communities, 1996
59. 59. Commission of the European Communities. European pharmaceutical research, development and innovation: assessment of the socio-economic impact of new drugs. Seville: Institute for Prospective Technological Studies, 1997
60. 60. Meyers AS. Rare diseases: what patients need. In: Thoene JG, editor. Physicians' guide to rare diseases. National Organisation for Rare Disorders' (NORD) textbook. 2nd ed. Montvale (NJ): Dowden Publishing Company, 1995
61. 61. Hall B. The private and social returns to R & D: measurement and findings. In: Anderson J, Fears R, editors. Valuing and evaluating: assessment of the value of R & D in creating national and corporate prosperity. London: SB, 1996
62. 62. Commission of the European Communities. European pharmaceutical research, development and innovation: assessment of the socioeconomic impact of new drugs. Seville: Institute for Prospective Technological Studies, 1997